Standard BioTools Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Standard BioTools Inc. - overview
Established
1999
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Standard BioTools Inc. specializes in life sciences tools, focusing on spatial biology and high-throughput genomics to enhance research capabilities across various scientific domains. Standard BioTools Inc. develops innovative tools for the life sciences sector.
The company was founded in 1999 and is headquartered in San Francisco, US. Founded by William Roche, Standard BioTools has received funding through multiple rounds, with the most recent round being a PIPE, raising USD 250. 00 mn from investors Casdin Capital and Viking Global Investors. The total amount raised by the company is USD 250.
00 mn, and they have completed a total of 9 deals, with the latest deal occurring on February 15, 2011. Standard BioTools specializes in advanced life sciences tools, focusing on spatial biology and high-throughput genomics. Their core offerings include the CyTOF XT PRO, Hyperion XTi Imaging System, and the Biomark X9 System. These products enable multiplexed tissue imaging and genomic analysis, facilitating applications like immune profiling and biomarker discovery.
The company primarily serves research institutions, pharmaceutical companies, and biotechnology firms in North America, Europe, and Asia, catering to diverse fields from immuno-oncology to sustainable agriculture. In 2022, Standard BioTools generated revenue of USD 72. 45 mn, while reporting an EBITDA of USD -100. 35 mn for the same year.
The company earns revenue through the sales of its instruments and related reagents, engaging in direct sales to research labs and potential partnerships with pharmaceutical firms. Standard BioTools aims to leverage recent funding to support the development of new products and expand its market reach. The company is focusing on launching new products designed for enhanced genomic analysis, although specific release dates are not detailed. Additionally, they plan to target expansion into new geographic regions, which will be outlined in their strategic initiatives as they advance.
The funding raised in the PIPE deal will assist in financing these growth efforts, paving the way for broader market penetration and innovation in their product lines.
Current Investors
Viking Global Investors, Casdin Capital, Alloy Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Analytics & Performance Software
Website
www.fluidigm.com
Verticals
Artificial Intelligence
Company Stage
Mature
Total Amount Raised
Subscriber access only
Standard BioTools Inc. - timeline of key events
Standard BioTools Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 42,865,000 | 52,334,000 | 71,183,000 | 116,456,000 | 114,712,000 | 104,446,000 | 101,937,000 | 112,964,000 | 117,243,000 | 138,144,000 | 32,794,000 | 72,454,000 | - | - | - |
| % Revenue Growth (YoY) | - | 22.1% | 36.0% | 63.6% | (1.5%) | (8.9%) | (2.4%) | 10.8% | 3.8% | 17.8% | (76.3%) | 120.9% | - | - | - |
| EBITDA (USD) | (17,322,000) | (15,880,000) | (16,102,000) | (37,975,000) | (34,040,000) | (55,252,000) | (39,751,000) | (23,213,000) | (34,098,000) | (32,550,000) | (15,120,000) | (100,348,000) | - | - | - |
| Operating Income (USD) | (18,566,000) | (18,071,000) | (18,653,000) | (51,836,000) | (50,155,000) | (73,190,000) | (58,360,000) | (48,164,000) | (51,839,000) | (51,036,000) | (19,320,000) | (116,205,000) | - | - | - |
| Operating Margin | (43.3%) | (34.5%) | (26.2%) | (44.5%) | (43.7%) | (70.1%) | (57.3%) | (42.6%) | (44.2%) | (36.9%) | (58.9%) | (160.4%) | - | - | - |
| % EBITDA Margin | (40.4%) | (30.3%) | (22.6%) | (32.6%) | (29.7%) | (52.9%) | (39.0%) | (20.5%) | (29.1%) | (23.6%) | (46.1%) | (138.5%) | - | - | - |
| NET Income (USD) | (22,470,000) | (19,024,000) | (16,526,000) | (52,830,000) | (53,315,000) | (75,985,000) | (60,535,000) | (59,013,000) | (64,790,000) | (53,020,000) | (18,821,000) | (190,098,000) | - | - | - |
| % Net Margin | (52.4%) | (36.4%) | (23.2%) | (45.4%) | (46.5%) | (72.8%) | (59.4%) | (52.2%) | (55.3%) | (38.4%) | (57.4%) | (262.4%) | - | - | - |
Standard BioTools Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Standard BioTools Inc. | - |
Displaying 1 - 1 of 1
Standard BioTools Inc. - employee data
Standard BioTools Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.